

# GENERAL AGREEMENT ON TARIFFS AND TRADE

RESTRICTED

TBT/Notif.86.2  
14 January 1986

Special Distribution

## Committee on Technical Barriers to Trade

### NOTIFICATION

The following notification is being circulated in accordance with Article 10.4.

1.	Party to Agreement notifying: <u>UNITED STATES</u>
2.	Agency responsible: Food and Drug Administration (233)
3.	Notified under Article 2.5.2 <input checked="" type="checkbox"/> , 2.6.1 <input type="checkbox"/> , 7.3.2 <input type="checkbox"/> , 7.4.1 <input type="checkbox"/> , Other:
4.	Products covered (CCCN where applicable, otherwise national tariff heading): Oral aspirin-containing drug products (CCCN Chapter 30)
5.	Title: Proposed labelling for oral aspirin-containing drug product
6.	Description of content: The Food and Drug Administration is proposing to require the labelling of oral over-the-counter aspirin and aspirin-containing drug products for human use to bear a warning that such products should not be used to treat chicken-pox or flu symptoms in children or teenagers before consulting a doctor about Reye syndrome, a rare but serious illness.
7.	Objective and rationale: To bring uniformity and consistency to the market-place and to aid in increasing public awareness
8.	Relevant documents: 50 FR 51400, 17 December 1985; 21 CFR. Will appear in the Federal Register when adopted.
9.	Proposed dates of adoption and entry into force: These requirements are proposed to become effective for products initially introduced or initially delivered for introduction into inter-State commerce ninety days after the date of publication of any final rule based on this proposal or 30 May 1986, whichever is later.
10.	Final date for comments: 15 January 1986
11.	Texts available from: National enquiry point <input checked="" type="checkbox"/> or address of other body: